A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes


Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, Hassan Hartman, Alessandra Løchen, Thomas P. Peacock & Christopher Ruis Nature (2023) Cite this article Abstract Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during replication. Most random mutations are likely to be deleterious to the virus and many will be lethal; thus, molnupiravir-induced […]

COVID-19 Therapeutics for Nonhospitalized Patients


Rajesh T. Gandhi, MD1; Preeti N. Malani, MD, MSJ2,3; Carlos del Rio, MD4, JAMA. 2022;327(7):617-618. doi:10.1001/jama.2022.0335 Substantial progress has been made in therapeutics for nonhospitalized patients with COVID-19, but supply of and access to treatment remain limited. This Viewpoint summarizes currently available therapeutics for nonhospitalized patients in the setting of the Omicron variant including principles for equitable allocation. Patients with mild or moderate COVID-19 […]